Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy
Conclusion:
Considering this remarkable response to crizotinib, we can safely conclude that patients with squamous cell lung cancer should have the option of undergoing ALK testing to determine if there is indication for crizotinib treatment even after they have failed chemotherapy.
Source: BMC Pulmonary Medicine - Latest articles - Category: Respiratory Medicine Authors: Qiushi WangYong HeXin YangYubo WangHualiang Xiao Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Chemotherapy | CT Scan | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | PET Scan | Respiratory Medicine | Squamous Cell Carcinoma | Translocation